Hello,
Today in
One giant question is swirling around the IPO of hot health insurer Oscar: Can the startup ever make money?
- Insurance startup
Oscar Health is going public at a valuation of $8 billion. - Oscar has been plagued by heavy losses totaling $1.4 billion, because it's struggled to tame administrative and healthcare costs.
- Some experts said Oscar may find opportunity in Medicare Advantage or selling its software.
Read the full analysis from Shelby Livingston here>>
A new kind of biotech upstart inspired by a top MIT finance professor received a crucial validation, and rivals are now copying its strategy. BridgeBio's CEO says it's just getting started.
- The FDA approved
BridgeBio 's first drug, for a disease that affects 100 children in the US and Europe. - BridgeBio mitigates risk with a "hub-and-spoke" model, with a central management team and subsidiaries.
- The model is gaining in popularity in biopharma and could reshape drug R&D, McKinsey & Co. says.
Read the full story from Allison DeAngelis here>>
How companies like Walmart and Best Buy have curtailed their ambitions to upend the $3.8 trillion healthcare industry
- America's biggest
retail chains have been pushing into healthcare with mixed results. - The pandemic has cemented the shift into healthcare for some retailers, while others have slowed their efforts.
- Here's how healthcare strategies from CVS Health, Walgreens, Walmart, and Kroger have played out.
Read the full story from Patricia Kelly Yeo here>>
More stories we're reading:
- Why Johnson & Johnson's COVID-19 vaccine is probably the best shot (Insider)
- A Marshall Project survey found out how people who are incarcerated feel about vaccines (The Marshall Project)
- 67 Black CEOs and executives - including execs from Walmart Health, UnitedHealth Group, and Humana - share their experiences in corporate America (Insider)
- Why vaccines delivered through the nose might be key to beating COVID-19 (Scientific American)
- Lydia